Literature DB >> 11121545

A multiple transgenic mouse model with a partially humanized activation pathway for helper T cell responses.

R Laub1, M Dorsch, D Meyer, J Ermann, H J Hedrich, F Emmrich.   

Abstract

Mice expressing human CD4 and human MHC II molecules provide a valuable model both for the investigation of the immunopathogenetic role of human autoantigens and for the development of therapeutic strategies based on modulating helper T cell activation in vivo. Here we present a novel mouse model expressing HLA-DR17 (a split antigen of HLA-DR3) together with human CD4 in the absence of murine cd4 (CD4/DR3 mice). Human CD4 accurately replaces murine cd4 within T cells. In particular, the preservation of cd8(+) and CD4(+) T cell subsets distinguishes CD4/DR3 mice from other multiple transgenic models in which the alternative T cell subsets are fundamentally disturbed. Moreover, human CD4 is also faithfully expressed on antigen presenting cells such as dendritic cells and monocyte/macrophages, so that the overall transgenic CD4 expression pattern resembles very closely that of humans. HLA-DR3 expression in the thymus correlates very closely to that of mouse MHC II. In contrast, only 70% of mouse MHC II positive cells in spleen, lymph node, and peripheral blood coexpress HLA-DR3. No significant bias was found with regard to particular leucocytes in this respect. The stimulation of helper T cells clearly depends on the interaction between the human transgene products, since mAbs to HLA-DR and/or CD4 completely blocked in vitro recall responses to tetanus toxoid. CD4/DR3 mice represent a partially humanized animal model which will facilitate studies of DR3-associated autoimmune responses and the in vivo determination of the therapeutic potential of mAbs to human CD4.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11121545     DOI: 10.1016/s0022-1759(00)00288-x

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

1.  Th1 and Th17 immunocompetence in humanized NOD/SCID/IL2rgammanull mice.

Authors:  Deepika Rajesh; Ying Zhou; Ewa Jankowska-Gan; Drew Allan Roenneburg; Melanie L Dart; Jose Torrealba; William J Burlingham
Journal:  Hum Immunol       Date:  2010-03-26       Impact factor: 2.850

2.  Characterization of murine non-adherent bone marrow cells leading to recovery of endogenous hematopoiesis.

Authors:  Stephan Fricke; Christian Fricke; Christopher Oelkrug; Nadja Hilger; Uta Schönfelder; Manja Kamprad; Jörg Lehmann; Johannes Boltze; Frank Emmrich; Ulrich Sack
Journal:  Cell Mol Life Sci       Date:  2010-06-18       Impact factor: 9.261

3.  Prevention of graft-versus-host-disease with preserved graft-versus-leukemia-effect by ex vivo and in vivo modulation of CD4(+) T-cells.

Authors:  Stephan Fricke; Nadja Hilger; Christian Fricke; Uta Schönfelder; Gerhard Behre; Peter Ruschpler; Andreas Boldt; Christopher Oelkrug; Ulrich Sack; Frank Emmrich
Journal:  Cell Mol Life Sci       Date:  2013-09-26       Impact factor: 9.261

Review 4.  Antibody- and aptamer-strategies for GvHD prevention.

Authors:  Christopher Oelkrug; Ulrich Sack; Andreas Boldt; Isis C Nascimento; Henning Ulrich; Stephan Fricke
Journal:  J Cell Mol Med       Date:  2014-10-29       Impact factor: 5.310

Review 5.  The Epitope-Specific Anti-human CD4 Antibody MAX.16H5 and Its Role in Immune Tolerance.

Authors:  Lilly Stahl; Anna Duenkel; Nadja Hilger; Uta Sandy Tretbar; Stephan Fricke
Journal:  Front Immunol       Date:  2019-05-24       Impact factor: 7.561

6.  Allogeneic non-adherent bone marrow cells facilitate hematopoietic recovery but do not lead to allogeneic engraftment.

Authors:  Stephan Fricke; Manuela Ackermann; Alexandra Stolzing; Christoph Schimmelpfennig; Nadja Hilger; Jutta Jahns; Guido Hildebrandt; Frank Emmrich; Peter Ruschpler; Claudia Pösel; Manja Kamprad; Ulrich Sack
Journal:  PLoS One       Date:  2009-07-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.